Retour
Prix Starpharma Holdings Ltd (SPHRY)
Graphique du cours de l'action SPHRY
SPHRY Gagner
Starpharma Holdings Ltd
$2.3
-11.53%
$-0.3
À la fermeture : Jan 16, 16:00:00 GMT-5
$2.3
0%
$0
Post-Marché: Jan 16, 20:00:00 GMT-5
Statistiques clés
Clôture préc.
$2.6
Prix d'ouverture
$2.3
Plage de la journée
$2.3 - $2.3
Plage de 52 semaines
$0.47 - $2.86
Volume
1.1K
Volume moyen
1.0K
BPA (TTM)
-0.16
Rendement en dividend
--
Capitalisation boursière
$96.1M
Qu’est-ce que SPHRY ?
Starpharma Holdings Ltd. engages in the research, development, and commercialization of dendrimer products for pharmaceutical and healthcare applications. The firm's principal activities are focused on the research, development and commercialization of dendrimer technology for pharmaceutical and healthcare applications. The firm's portfolio of dendrimer-based products includes three clinical-stage dendrimer enhanced product (DEP) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over the counter (OTC) products. Its clinical-stage assets, DEP SN38, DEP cabazitaxel, and DEP docetaxel, are dendrimer-based chemotherapeutic drugs. Additionally, the Company has a preclinical pipeline of DEP radiopharmaceuticals in development. The company also manufactures and sells SPL7013 (astodrimer sodium) proprietary products: VivaGel BV, Viraleze nasal spray, and VivaGel condom. The firm has applied its DEP technology to the innovative area of antibody-drug conjugates.
Fonctionnalités
Stratégies de trading
Ressources
© 2025 Finture Development Limited. All rights reserved